Research Insights

patient-partnered-ai-beta-dystroglycan-dmd

A New Look. The Same Purpose. We’re excited to introduce the new AlgorithmicRx logo — a refreshed identity that reflects our journey forward. While our logo has changed, our vision and mission remain exactly the same: to harness AI and advanced computational approaches to accelerate drug discovery and transform the path toward better therapies for rare diseases. New logo. Same vision. Same mission. Bigger ambition.

On World Duchenne Awareness Day 2026 (WDAD26), we pause to recognize every child and family living with Duchenne muscular dystrophy—and the researchers, clinicians, advocates, and innovators working toward a better future. For AlgorithmicRx, this mission is deeply personal. When a child is diagnosed with Duchenne, a fierce and resilient mother is reborn with a determination to change the trajectory. The diagnosis does not simply change a family’s plans; it changes how a mothe

In the rapidly evolving landscape of structural biology and AI-native drug discovery, the frontier is moving faster than ever. Almost weekly, new computational models are released, each claiming to outperform previous benchmarks on critical macromolecular structure prediction tasks. For a lean, mission-driven startup like AlgorithmicRx, this explosion of open-science tools is a massive equalizer. But it also introduces a critical scientific question: How do we separate model-

One of the quieter shifts happening in drug discovery right now isn’t a new drug class — it’s a change in where the design work happens. Increasingly, the first draft of a therapeutic molecule is built not on a lab bench, but inside a cloud computing job, using a protein language model to propose a structure before a single reagent is touched. At AlgorithmicRx, we spend a lot of time evaluating tools like this, because the computational front-end of drug discovery is exactly

At AlgorithmicRx, our mission has always been clear: accelerate the discovery of transformative therapies for rare diseases by combining deep biology with artificial intelligence. As our platform advances into the MVP stage, we are continuing to refine not only how we identify therapeutic targets, but also how we build biological confidence around them before moving into downstream drug design. Beyond Target Discovery Our AI platform integrates diverse biological data—includi

The AlgorithmicRx team participated virtually in July 29's U.S. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting reviewing Capricor Therapeutics' Biologics License Application (BLA) for Deramiocel as a potential treatment for Duchenne muscular dystrophy (DMD). Following presentations from FDA reviewers, Capricor Therapeutics, scientific experts, physicians, patients, caregivers, and advocacy organizations, the Advisor

We're building a computational proof-of-concept (POC) that uses AlphaFold 3 to discover compensatory proteins capable of restoring a critical structural link broken in DMD: from disease hypothesis to in silico validation The Problem Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene , that leave the protein truncated or missing entirely. Dystrophin normally acts as a molecular shock absorber, anchoring the cell's internal actin skeleton to the...